Wegovy Is a Brand Name Built on the Drug Semaglutide

Wegovy vs Semaglutide at a Glance

"Semaglutide" is the chemical name for the drug. "Wegovy" is one specific, trademarked product built on that drug, approved by the FDA for chronic weight management. The table below separates the brand from the umbrella term.

What Semaglutide Means When You See It Online

Semaglutide by itself names a molecule. It is not a product you can order on its own. Treating the two as identical causes most of the confusion between it and Wegovy.

The same molecule reaches patients through four separate paths today. Wegovy is the weekly injectable version approved specifically for weight management. Ozempic is the weekly injectable version approved for type 2 diabetes, at a lower maximum dose. The Wegovy pill is a newer, higher-dose oral tablet approved for weight management, distinct from the diabetes-focused oral tablet sold under the Ozempic name. And compounded semaglutide is an unbranded version mixed by a licensed pharmacy rather than manufactured by Novo Nordisk. Two of those four paths come as a pill instead of a shot. See our oral GLP-1 pills comparison for the full breakdown of both approved tablets, and our oral vs injectable semaglutide breakdown for how the Ozempic tablet compares to the shot.

A site advertising "semaglutide" without naming Wegovy or Ozempic is almost always selling the compounded version. The branded products are only available by prescription, filled through a pharmacy that carries the actual Novo Nordisk product.

The Approved Use Behind Each Name

Wegovy carries an indication for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Ozempic carries a separate indication for type 2 diabetes. Its label does not include weight management as an approved use, even though many prescribers use it off-label for that purpose.

This distinction is not paperwork. Wegovy is approved to reach a higher dose, up to 2.4 mg weekly, against a 2 mg weekly maximum on the Ozempic label. The clinical trials behind each approval measured different outcomes in different populations too. Insurance coverage frequently follows the label. A plan that covers Ozempic for diabetes may deny the identical drug sold as Wegovy for a weight-management diagnosis, and vice versa.

Semaglutide as a bare compounded product carries no FDA-reviewed indication at all, because compounded drugs are not independently evaluated for safety and efficacy the way a branded product is. A pharmacist mixes it under a prescriber's order. No FDA approval covers the compounded product itself.

Compounded Semaglutide Sold as a Wegovy Alternative

Compounded semaglutide became widely available while the branded drug faced supply shortages. Its legal footing is tied directly to that shortage status. When Wegovy or Ozempic comes off the FDA's shortage list, the rules that let pharmacies mass-produce a compounded copy tighten sharply. Some previously available products stop being legal to compound at scale.

The FDA has warned specifically about compounded products using semaglutide salt forms, such as semaglutide sodium or semaglutide acetate. Those salt forms are chemically different from the base semaglutide molecule studied in Wegovy's clinical trials and approved on its label. A product built on a salt form is not simply a cheaper Wegovy. It is an unstudied variant, and the agency has linked adverse event reports to exactly this substitution.

Sourcing is the practical safeguard. A licensed 503A or 503B compounding pharmacy that confirms it uses base semaglutide rather than a salt form carries a meaningfully different risk profile than an unregulated seller. That unregulated category markets "research-use" semaglutide with no prescription required, and it sits entirely outside FDA oversight.

Who Should Look Elsewhere

Skip both options if you are currently pregnant or planning pregnancy. Semaglutide in any form carries a pregnancy warning on its label regardless of brand. The same goes for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The FDA specifically warns against using any semaglutide product in those cases.

Anyone already stable on a prescribed dose of Wegovy or Ozempic through their own doctor does not need to weigh a switch to a compounded alternative. That decision belongs in a conversation with the prescriber who is tracking your labs and response. A price table cannot make that call.

What Would Change the Verdict

Two developments would shift the picture the most. The first is a semaglutide patent expiration or a generic entrant reaching the US market. That would give "semaglutide" a legal, FDA-reviewed generic meaning for the first time, separate from both the Novo Nordisk brands and unregulated compounding. The second is a sustained end to FDA shortage status for both Wegovy and Ozempic. That would close off most large-scale legal compounding and leave brand pricing and insurance coverage as the deciding factors instead of the current cost gap.

Novo Nordisk cutting its list price, something it has already done under public and competitive pressure in past years, would also narrow the price gap at the center of this trade-off.

The Yearly Cost Gap in Real Numbers

Run the arithmetic over a full year and the gap between the two paths gets harder to ignore. Wegovy at its roughly $1,300 monthly list price runs close to $15,600 a year before any savings card or insurance offset. A manufacturer savings card can cut that toward $8,400 to $12,000 a year for people who qualify. Insurance coverage, where it applies, can bring the out-of-pocket total down further still.

Compounded semaglutide at $150 to $350 a month lands between roughly $1,800 and $4,200 a year. That figure excludes the pharmacy consultation and monitoring costs most reputable compounding programs also charge. Even against a Wegovy savings card, the gap often runs several thousand dollars a year. A straight price comparison misses what that gap buys. It buys an FDA-verified pen with a fixed dose in every injection. A compounded version's consistency depends on the pharmacy behind it instead.

The Bottom Line

Wegovy and semaglutide are not two competing drugs. Wegovy is one regulated, branded way to get semaglutide, with a quality guarantee and an FDA-reviewed weight-management indication behind it. "Semaglutide" as a standalone shopping term almost always points to a compounded product carrying a weaker guarantee and a legal status tied to shortage rules that can change without notice.

Cost is the main reason people consider the compounded route, and quality assurance is the main reason to stay with the branded product. Neither side of that trade-off is right for every reader, which is exactly why it belongs in front of a prescriber who knows your history. A price comparison alone should not settle it. Our compounded semaglutide vs Ozempic page covers the same trade-off from the diabetes-brand side, and our oral GLP-1 pills comparison covers the tablet versions of both drugs.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

GE

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →